Luina Bio plans to expand its new Bio-manufacturing GMP and development facility.
The initial stage expansion includes the opening of additional small scale (30L) GMP manufacturing suites, development of 4 additional laboratories. The second stage of the expansion features the development of a 10,000m2 late phase clinical and commercial production facility. In addition, the new expanded facility for bacterial and yeast recombinant projects include vaccine manufacturing for COVID-19.
The new facility consists of five production lines in parallel with the advancement of new technologies. The production time of live biotherapeutics and bacterial recombinant biotherapy projects will be reduced with the addition of new technologies.
The initial expansion of the new GMP manufacturing suite for a clinical project is expected to start its operation in Q3 2020 while the opening of the 500L process development site is set to open in Q4 2020. Moreover, the second stage commercial production facility with 10,000m2 is aimed to start its operation in late 2021.
The expansion benefits by adding 300 new technical and scientific staff.
Small scale GMP manufacturing suites (First Stage Expansion) Q3 2020, Next Phase Commercial Facility 2021.